Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

adma biologics inc - ADMA

ADMA

Close Chg Chg %
19.49 0.05 0.26%

Open Market

19.54

+0.05 (0.26%)

Volume: 810.94K

Last Updated:

Dec 24, 2025, 1:00 PM EDT

Trade Now

Company Overview: adma biologics inc - ADMA

ADMA Key Data

Open

$19.57

 Day Range

19.36 - 19.69

52 Week Range

13.50 - 25.67

 Market Cap

$4.64B

Shares Outstanding

238.00M

 Public Float

229.92M

Beta

0.43

 Rev. Per Employee

N/A

P/E Ratio

22.95

 EPS

$0.88

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

2.57M

  

ADMA Performance

1 Week
 
 -0.20%
 
1 Month
 
 1.88%
 
3 Months
 
 25.18%
 
1 Year
 
 11.98%
 
5 Years
 
 808.84%
 

ADMA Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 3
Full Ratings ➔

About adma biologics inc - ADMA

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

ADMA At a Glance

ADMA Biologics, Inc.
465 State Route 17 South
Ramsey, New Jersey 07446
Phone 1-201-478-5552 Revenue 426.45M
Industry Biotechnology Net Income 197.67M
Sector Health Technology 2024 Sales Growth 65.155%
Fiscal Year-end 12 / 2025 Employees 685
View SEC Filings

ADMA Valuation

P/E Current 23.347
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 21.113
Price to Sales Ratio 9.786
Price to Book Ratio 11.627
Price to Cash Flow Ratio 35.17
Enterprise Value to EBITDA 28.242
Enterprise Value to Sales 9.737
Total Debt to Enterprise Value 0.02

ADMA Efficiency

Revenue/Employee 622,560.584
Income Per Employee 288,573.723
Receivables Turnover 8.529
Total Asset Turnover 1.031

ADMA Liquidity

Current Ratio 5.967
Quick Ratio 2.902
Cash Ratio 1.857

ADMA Profitability

Gross Margin 51.392
Operating Margin 32.59
Pretax Margin 29.479
Net Margin 46.353
Return on Assets 47.772
Return on Equity 81.645
Return on Total Capital 45.85
Return on Invested Capital 56.038

ADMA Capital Structure

Total Debt to Total Equity 23.528
Total Debt to Total Capital 19.047
Total Debt to Total Assets 16.477
Long-Term Debt to Equity 23.179
Long-Term Debt to Total Capital 18.764
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Adma Biologics Inc - ADMA

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
80.94M 154.08M 258.21M 426.45M
Sales Growth
+91.72% +90.36% +67.59% +65.15%
Cost of Goods Sold (COGS) incl D&A
80.48M 119.53M 170.00M 207.29M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
5.50M 7.11M 8.33M 8.04M
Depreciation
4.78M 6.40M 7.61M 7.66M
Amortization of Intangibles
715.35K 715.35K 724.00K 388.00K
COGS Growth
+29.80% +48.51% +42.22% +21.94%
Gross Income
457.93K 34.55M 88.22M 219.16M
Gross Income Growth
+102.31% +7,444.76% +155.34% +148.44%
Gross Profit Margin
+0.57% +22.42% +34.16% +51.39%
2021 2022 2023 2024 5-year trend
SG&A Expense
59.07M 74.13M 66.59M 80.18M
Research & Development
3.89M 3.83M 3.30M 1.81M
Other SG&A
55.19M 70.30M 63.29M 78.37M
SGA Growth
+30.90% +25.49% -10.17% +20.42%
Other Operating Expense
- - - -
-
Unusual Expense
- 6.67M 26.17M 1.24M
EBIT after Unusual Expense
(58.61M) (46.25M) (4.54M) 137.74M
Non Operating Income/Expense
(217.05K) (589.56K) 1.33M 1.90M
Non-Operating Interest Income
34.53K 44.83K 1.62M 2.10M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
13.06M 19.28M 25.03M 13.93M
Interest Expense Growth
+8.94% +47.66% +29.81% -44.34%
Gross Interest Expense
13.06M 19.28M 25.03M 13.93M
Interest Capitalized
- - - -
-
Pretax Income
(71.89M) (66.12M) (28.24M) 125.71M
Pretax Income Growth
+5.10% +8.03% +57.29% +545.18%
Pretax Margin
-88.81% -42.91% -10.94% +29.48%
Income Tax
- (239.59K) (211.34K) (71.96M)
Income Tax - Current - Domestic
- - - 12.32M
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - (84.28M)
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - 239.59K 211.34K
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(71.65M) (65.90M) (28.24M) 197.67M
Minority Interest Expense
- - - -
-
Net Income
(71.65M) (65.90M) (28.24M) 197.67M
Net Income Growth
+5.41% +8.02% +57.15% +800.00%
Net Margin Growth
-88.52% -42.77% -10.94% +46.35%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(71.65M) (65.90M) (28.24M) 197.67M
Preferred Dividends
- - - -
-
Net Income Available to Common
(71.65M) (65.90M) (28.24M) 197.67M
EPS (Basic)
-0.5133 -0.3331 -0.1261 0.8481
EPS (Basic) Growth
+41.62% +35.11% +62.14% +772.56%
Basic Shares Outstanding
139.58M 197.87M 223.98M 233.08M
EPS (Diluted)
-0.5133 -0.3331 -0.1261 0.8123
EPS (Diluted) Growth
+41.62% +35.11% +62.14% +744.17%
Diluted Shares Outstanding
139.58M 197.87M 223.98M 243.34M
EBITDA
(53.12M) (32.46M) 29.96M 147.03M
EBITDA Growth
+12.88% +38.88% +192.30% +390.68%
EBITDA Margin
-65.62% -21.07% +11.60% +34.48%

Snapshot

Average Recommendation BUY Average Target Price 30.667
Number of Ratings 3 Current Quarters Estimate 0.185
FY Report Date 12 / 2025 Current Year's Estimate 0.585
Last Quarter’s Earnings 0.16 Median PE on CY Estimate N/A
Year Ago Earnings 0.488 Next Fiscal Year Estimate 0.88
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 2 2 2 2
Mean Estimate 0.19 0.19 0.59 0.88
High Estimates 0.20 0.20 0.60 0.94
Low Estimate 0.17 0.18 0.57 0.82
Coefficient of Variance 11.47 7.44 3.63 9.64

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 3 4 3
OVERWEIGHT 0 0 0
HOLD 0 0 1
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Overweight

Insider Actions for Adma Biologics Inc - ADMA

Date Name Shares Transaction Value
Jul 29, 2025 Brad Tade CFO and Treasurer 239,419 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $17.31 per share 4,144,342.89
Jul 29, 2025 Kaitlin Kestenberg COO and SVP, Compliance 487,398 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $17.31 per share 8,436,859.38
Mar 24, 2025 Adam S. Grossman President and CEO; Director 855,950 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 24, 2025 Adam S. Grossman President and CEO; Director 2,061,850 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $18.92 per share 39,010,202.00
Mar 24, 2025 Adam S. Grossman President and CEO; Director 2,082,850 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $5.4 per share 11,247,390.00
Mar 24, 2025 Adam S. Grossman President and CEO; Director 2,067,850 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $18.92 per share 39,123,722.00
Mar 11, 2025 Kaitlin Kestenberg COO and SVP, Compliance 509,345 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $17.02 per share 8,669,051.90
Feb 24, 2025 Brad Tade CFO and Treasurer 93,023 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 24, 2025 Lawrence P. Guiheen Director 164,830 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 24, 2025 Eduardo Rene Salas Director 16,279 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 24, 2025 Eduardo Rene Salas Director 10,889 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 24, 2025 Adam S. Grossman President and CEO; Director 376,744 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 24, 2025 Young T. Kwon Director 16,279 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 24, 2025 Young T. Kwon Director 252,330 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 24, 2025 Jerrold B. Grossman Director 16,279 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 24, 2025 Jerrold B. Grossman Director 478,194 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 24, 2025 Alison C. Finger Director 16,279 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 24, 2025 Alison C. Finger Director 34,929 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 24, 2025 Steven Arnote Elms Director 16,279 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 24, 2025 Steven Arnote Elms Director 87,330 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Adma Biologics Inc in the News